News

Kite, a Gilead Company, presented promising data on Tecartus (brexucabtagene autoleucel) for relapsed/refractory mantle cell lymphoma (R/R MCL) and...

The DREAMM-7 trial interim analysis revealed that belantamab mafodotin combined with bortezomib and dexamethasone (BVd) significantly improved overall survival...

Star Therapeutics announced interim Phase 1 clinical trial data for VGA039, a novel subcutaneous monoclonal antibody for Von Willebrand...

Stoke Therapeutics announced positive data from Phase 1/2a and open-label extension (OLE) studies of zorevunersen, a drug candidate for...

PureTech Health presented positive Phase 1b trial data for LYT-200, a novel anti-galectin-9 monoclonal antibody, in patients with relapsed...

Arcellx, a biotechnology company, announced positive Phase 2 iMMagine-1 study data for anitocabtagene autoleucel (anito-cel), a CAR T-cell therapycell...

Indapta Therapeutics and Sanofi are collaborating to investigate the combined efficacy and safety of Indapta’s allogeneic g-NK cell therapy,...

A new study from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) demonstrates that a donor search...

Merck announced positive Phase 2 trial data for zilovertamab vedotin, an investigational antibody-drug conjugate targeting ROR1, in combination with...

Orca Bio presented positive three-year follow-up data for its allogeneic T-cell immunotherapy, Orca-T, at the 66th American Society of...